Investor Presentaiton slide image

Investor Presentaiton

Reconciliation of IFRS and Non-IFRS Results Adjusted EBITDA Net loss Depreciation Interest expense (income) Foreign exchange loss (gain) Fair value loss on financial instruments (1) Listing fee Forfeited SPAC transaction cost Share-based compensation (2) Adjusted EBITDA loss 2020 $(4,433) 378 (U.S. dollar amounts in thousands) Three months ended October 31, 2021 $(204,969) 1,069 2,040 Year ended October 31, 2021 $(226,559) 2,899 2,970 2020 189 222 (336) 758 35,821 84 38,254 $(9,276) 1,095 495 (446) 84 152,719 152,719 2,000 1,588 $(11,510) 1,588 $(4,119) $(25,370) $(8,047) (1) Fair value loss on financial instruments relates to warrants, convertible debt, and restricted share units liability. (2) Share-based compensation relates to accelerated vesting of existing stock options upon completion of the Business Combination. Li-Cycle reports its financial results in accordance with the International Financial Reporting Standards ("IFRS"). The Company makes references to certain non-IFRS measures, including Adjusted EBITDA. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing a further understanding of the Company's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for the analysis of the Company's financial information reported under IFRS. Li-Cycle defines Adjusted EBITDA as earnings before depreciation and amortization, interest expense (income), income tax expense (recovery), foreign exchange (gain) loss, fair value (gain) loss on financial instruments, and non-recurring expenses such as forfeited SPAC transaction cost, listing fee, and accelerated vesting of share-based compensation related to the Business Combination. Li-Cycle 19
View entire presentation